Tests: A New Generation - Active Surveillance

  1. Did the Oncotype DX test impact your decision to choose active surveillance? Patient Dan Woska explains how the Oncotype DX test results helped him to conclude that active surveillance was appropriate for his prostate cancer. Published on Oct 16, 2017
  1. Does the Oncotype DX Assay sometimes indicate a change in level of risk? Bela Denes, MD, (urologist), explains how the Oncotype DX Assay often leads to an improved understanding of the level of risk for a patient. Published on Oct 16, 2017
  1. What if my urologist doesn’t know about the Oncotype DX Assay? Bela Denes, MD, (urologist), explains that many prostate cancer patients may not yet be aware of the available genomic tests for prostate cancer. Published on Oct 16, 2017
  1. What is unique about the Oncotype DX Genomic prostate cancer diagnostic test? Dr. Bela Denes, Senior Director of Urology at Genomic Health, discusses the usefulness of the Oncotype DX Genomic Prostate test. Published on Mar 31, 2015
  1. What’s unique about the Prolaris prognostic test? Karen Kunz, BSN, C.U.R.N, a certified urology nurse at Myriad Genetics discusses the usefulness of the Prolaris prognostic test. Published on Mar 31, 2015